Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)

This study is ongoing, but not recruiting participants.
Columbia University
George Washington University
Information provided by (Responsible Party):
Natera, Inc. Identifier:
First received: March 1, 2012
Last updated: October 28, 2014
Last verified: October 2014

March 1, 2012
October 28, 2014
January 2012
April 2014   (final data collection date for primary outcome measure)
Sensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y. [ Time Frame: Between first trimester screening (10-14 weeks GA) and invasive testing (amniocentesis or CVS). ] [ Designated as safety issue: No ]
The primary objective is to determine the diagnostic capability of the test to detect autosomal aneuploidy (chromosomes 13, 18, 21) and sex aneuploidy (X and Y).
Same as current
Complete list of historical versions of study NCT01545674 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)

This prospective blinded study will assess the diagnostic capability of an informatics enhanced SNP based technology (Parental Support) to identify pregnant women who are carrying a fetus with an aneuploidy from fee floating DNA in the maternal blood.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA

Plasma Sample Prepared DNA

Non-Probability Sample

Pregnant Women

  • Trisomy 13
  • Trisomy 18
  • Trisomy 21
  • Aneuploidy
Procedure: Blood Draw
Blood will be drawn from the mother and father
Pregnant Women
Pregnant Women with elevated risk of trisomic pregnancy
Intervention: Procedure: Blood Draw
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
December 2015
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Singleton pregnancy
  2. Gestational age between 8 weeks 0 days and 23 weeks, 6 days by best obstetrical estimate
  3. Mother has a high or moderate risk for trisomy
  4. Mother is planning to have or has had an amniocentesis or chorionic villus sampling (CVS) procedure

Exclusion Criteria:

  1. Unavailability of the father to provide a genetic sample (e.g. sperm donor, non-paternity)
  2. Egg donor used
  3. Mother or father have known chromosomal abnormalities (including known balanced translocations)
  4. Participation in the study in a previous pregnancy
  5. Pregnancy is a result of IVF with pre-implantation genetic diagnosis
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   Ireland,   Italy,   Korea, Republic of,   Spain
Natera, Inc.
Natera, Inc.
  • Columbia University
  • George Washington University
  • National Institutes of Health (NIH)
Principal Investigator: Ronald Wapner, MD Columbia University
Natera, Inc.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP